| Revenue growth | FY26 total income grew 19.5% YoY to INR 4,163 million. |
|---|---|
| Margins | FY26 EBITDA margin 35.8%; expected to remain stable despite cost pressures. |
| Demand visibility | Strong visibility in pharma, food, and electronics testing verticals. |
| Management confidence | High; targets 20-25% CAGR and maintaining >35% EBITDA margins. |
Growth
FY26 PAT at ₹775M (+16.1% YoY) with healthy EBITDA margins of 35.8%.
Outlook
Targeting 20-25% CAGR; FY27 focuses on biologics execution and US subsidiary operationalization.
Risks
Geopolitical tensions impacting supply chains, rising input costs, and industry-wide talent attrition.
Earnings Call filed with NSE, NSE: VIMTALABS. Summary written with AI assistance from the document.
Vimta Labs Ltd: key numbers
- Share price
- ₹567.20
- Market cap
- ₹2,535 Cr
- Revenue (annual)
- ₹407.3 Cr
- Net profit (annual)
- ₹77.51 Cr
- P/E (TTM)
- 31.8×Sector 53.1×
- Promoter holding
- 35.67%-0.18% QoQ
- FII holding
- 4.41%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vimta Labs Ltd
All →Vimta Labs Employee Stock Options
Vimta Labs allotted 12,955 ESOP shares under its 2021 plan. Paid-up capital rose to ₹8,93,99,718, raising dilution for shareholders.
Vimta Labs Credit Rating
CARE Ratings has reaffirmed the bank facility ratings of Vimta Labs Limited. The disclosure updates stakeholders on the company's ongoing credit facilities.
Vimta Labs Price Movement Clarification
Vimta Labs clarified that recent increases in its share volume are due to market factors and not related to any undisclosed company information or developments.
Vimta Labs Adverse Business Impact
Vimta Labs reported a cyber security incident affecting its IT infrastructure. The company confirmed operations remain fully functional with no material impact identified thus far.
Vimta Labs Investor Presentation: Key Takeaways
Vimta Labs reported Q1 FY27 total income of INR 1,129 million, up 13.7% YoY. Strategy focuses on diversifying into Biologics (CRAD) and strengthening domestic food testing.
- Call
- Guides 25% growth
Vimta Labs Other Announcement
Vimta Labs Ltd filed its quarterly shareholding pattern disclosure for the period ending June 30, 2026, pursuant to SEBI Regulation 31(1)(b).